Amalgamated Bank Lowers Holdings in Insulet Co. (NASDAQ:PODD)

Amalgamated Bank lowered its position in shares of Insulet Co. (NASDAQ:PODD) by 8.3% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 17,260 shares of the medical instruments supplier’s stock after selling 1,558 shares during the period. Amalgamated Bank’s holdings in Insulet were worth $3,745,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in PODD. Los Angeles Capital Management LLC bought a new position in Insulet during the 4th quarter worth about $11,563,000. Natixis Advisors L.P. boosted its stake in shares of Insulet by 185.0% during the fourth quarter. Natixis Advisors L.P. now owns 29,883 shares of the medical instruments supplier’s stock valued at $6,484,000 after purchasing an additional 19,396 shares in the last quarter. LGT Group Foundation purchased a new position in Insulet during the fourth quarter valued at approximately $238,000. First Trust Direct Indexing L.P. bought a new position in Insulet in the fourth quarter worth approximately $305,000. Finally, Paces Ferry Wealth Advisors LLC purchased a new stake in Insulet during the fourth quarter worth $232,000.

Insider Buying and Selling at Insulet

In other news, Director Shacey Petrovic sold 11,609 shares of the business’s stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $162.92, for a total value of $1,891,338.28. Following the completion of the transaction, the director now owns 2,567 shares of the company’s stock, valued at approximately $418,215.64. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 0.47% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the company. Wolfe Research upgraded Insulet from a “peer perform” rating to an “outperform” rating and set a $200.00 price target on the stock in a report on Tuesday. JPMorgan Chase & Co. boosted their target price on shares of Insulet from $190.00 to $225.00 and gave the stock an “overweight” rating in a report on Friday, February 23rd. Piper Sandler lowered their price target on shares of Insulet from $250.00 to $230.00 and set an “overweight” rating on the stock in a report on Friday, February 23rd. Stifel Nicolaus boosted their price objective on shares of Insulet from $163.00 to $208.00 and gave the stock a “hold” rating in a research note on Monday, February 5th. Finally, Barclays lowered their target price on shares of Insulet from $214.00 to $213.00 and set an “equal weight” rating for the company in a research note on Monday, February 26th. Four research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $240.33.

Insulet Stock Up 1.1 %

Shares of PODD stock opened at $177.53 on Friday. The company has a debt-to-equity ratio of 1.86, a quick ratio of 2.62 and a current ratio of 3.51. Insulet Co. has a fifty-two week low of $125.82 and a fifty-two week high of $331.65. The firm has a market capitalization of $12.43 billion, a PE ratio of 61.01, a P/E/G ratio of 3.14 and a beta of 1.00. The stock’s 50-day simple moving average is $170.59 and its 200-day simple moving average is $181.63.

Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Thursday, February 22nd. The medical instruments supplier reported $1.40 EPS for the quarter, beating the consensus estimate of $0.67 by $0.73. The business had revenue of $509.80 million during the quarter, compared to analysts’ expectations of $461.26 million. Insulet had a net margin of 12.16% and a return on equity of 32.19%. The business’s quarterly revenue was up 37.9% compared to the same quarter last year. During the same period in the previous year, the business posted $0.55 EPS. Equities analysts expect that Insulet Co. will post 3.08 earnings per share for the current year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.